Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00051272 · ClinicalTrials.gov registry record · Phase 3
Effects Of Antidepressants On Sexual Functioning In Adults
A Phase 3 study of Major Depressive Disorder (MDD), sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 425
- Enrollment target
- 20
- Study locations
NCT00051272 is a Phase 3 study of Major Depressive Disorder (MDD) that has completed, run by GlaxoSmithKline. The registered enrollment target is 425 participants, above the 139-participant average among 22 other Major Depressive Disorder (MDD) trials with a reported enrollment target (206% higher). The trial reports 20 study locations across 17 states.
The verdict
NCT00051272, a Phase 3 study of Major Depressive Disorder (MDD), has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 425 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the effects of two antidepression medications on sexual functioning.
Conditions Studied
Interventions
- DRUG Extended-release Bupropion Hydrochloride
Study Locations (20)
Arizona
- GSK Investigational Site - Phoenix
- GSK Investigational Site - Scottsdale
Georgia
- GSK Investigational Site - Marietta
- GSK Investigational Site - Smyrna
Texas
- GSK Investigational Site - Bellaire
- GSK Investigational Site - San Antonio
California
- GSK Investigational Site - Berkeley
Connecticut
- GSK Investigational Site - Middletown
Delaware
- GSK Investigational Site - Wilmington
District of Columbia
- GSK Investigational Site - Washington D.C.
Florida
- GSK Investigational Site - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 425 participants |
| Start Date | 2003-01 |
| Est. Completion | 2004-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00051272
The ClinicalTrials.gov registry entry for NCT00051272 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 425 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 139-participant average among 22 other Major Depressive Disorder (MDD) trials with a reported enrollment target (206% higher). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depressive Disorder (MDD) appearing as the primary indexed condition, and to 1 intervention - of which Extended-release Bupropion Hydrochloride is the first listed.
NCT00051272 reports 20 study locations spanning 17 distinct geographic areas - top geographies include Arizona, Georgia, Texas.
Frequently Asked Questions
What is clinical trial NCT00051272 about?
NCT00051272 is a clinical study titled "Effects Of Antidepressants On Sexual Functioning In Adults". This study will evaluate the effects of two antidepression medications on sexual functioning.
What is the current status of trial NCT00051272?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 425 participants. The study started on 2003-01. Estimated completion is 2004-06.
What conditions does trial NCT00051272 study?
This clinical trial studies the following conditions: Major Depressive Disorder (MDD).
What interventions are being tested in trial NCT00051272?
The interventions under investigation include: Extended-release Bupropion Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00051272?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00051272 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Delaware, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder (MDD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
RECRUITING · Phase 3
-
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
RECRUITING · Phase 3
-
Switching From Generic Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) to Three Different Dose Initiation Strategies With Vilazodone
COMPLETED · Phase 3
-
Cognitive Rehabilitation for Veterans With MDD-related Cognitive Functioning Deficits
RECRUITING · NA
-
Neurofeedback to Treat Depression - 2
RECRUITING · NA
-
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.